• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Osteoporosis Rx Poor Within 6 Months of Hip Fracture

Slideshow

A new study found that post-hip fracture, less than 5% of elderly patients were started on osteoporosis medication despite high risk for recurrent fracture.

 Source: Desai RJ, Hahesri M, Abdia Y, et al. Association of osteoporosis medication use after hip fracture wth prevention of subsequent nonverteral fractures as an instrumental variable analysis. JAMA Network Open. 2018;1(3):e180826. doi:10.1001/jamanetworkopen.2018.0826 

Related Content
Exercise Plus Liraglutide May Preserve Bone Quality during Weight Loss: Daily Dose / image credit: ©New Africa/AdobeStock

Exercise Plus Liraglutide May Preserve Bone Quality during Weight Loss: Daily Dose

Sydney Jennings
July 16th 2024
Article

Your daily dose of the clinical news you may have missed.

Exercise Plus GLP-1 RA May Preserve BMD During Weight Loss, Study Finds / image credit, osteoporosis: ©Crevis/Shutterstock.com

Exercise Plus GLP-1 RA May Preserve BMD During Weight Loss, Study Finds

Grace Halsey
July 3rd 2024
Article

The preserved bone mass observed in participants taking liraglutide and exercising was seen despite weight reduction levels similar to outcomes with semaglutide and tirzepatide.

Biosimilars to Denosumab Win FDA Approval as Amgen and Sandoz Go to Court / image credit osteoporosis progression: ©crevis/stock.adobe.com

Two Biosimilars to Denosumab Win FDA Approval as Amgen and Sandoz Go to Court

Laura Joszt, MA
March 6th 2024
Article

Biosimilars Wyost and Jubobonti were approved as interchangeable for Xgeva and Prolia but launch will depend on the outcome of litigation between reference product manufacturers.

Daily Dose: Lack of Osteoporosis Screening, Treatment in Patients with Cirrhosis / image credit: ©New Africa/AdobeStock

Daily Dose: Lack of Osteoporosis Screening, Treatment in Patients with Cirrhosis

Sydney Jennings
January 19th 2024
Article

Your daily dose of the clinical news you may have missed.

Screening and Treatment for Osteoporosis Lacking in Patients with Cirrhosis, According to Real-World Analysis / Image credit: ©RFBSIP/AdobeStock

Screening and Treatment for Osteoporosis Lacking for Persons with Cirrhosis, According to Real-World Analysis

Sydney Jennings
January 12th 2024
Article

Less than a quarter of persons with cirrhosis who are diagnosed with osteoporosis are started on treatment, reported researchers.

Fracture risk reduction greater with denosumab vs alendronate osteoporotic femur image © Crevis/Adobe Stock

Denosumab Superior to Alendronate for Reduction of Postmenopausal Fracture Risk in Real-world Study

Grace Halsey
May 10th 2023
Article

Denosumab reduced RR of fracture vs alendronate across fracture types, eg, by 36% for hip fracture, by 43% for nonvertebral fractures, and by 30% for vertebral fractures.

© 2024 MJH Life Sciences

All rights reserved.